DOCSLIB.ORG

MEETING REPORT Updates on Histiocytic Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MEETING REPORT Updates on Histiocytic Disorders Pediatr Blood Cancer 2014;61:1329–1335 MEETING REPORT Updates on Histiocytic Disorders 1 y 2z 3# 4,5§ Sarah R. Vaiselbuh, MD, * Yenan T. Bryceson, PhD, MS, Carl E. Allen, MD, PhD, James A. Whitlock, MD, 4§ and Oussama Abla, MD Histiocytic disorders are rare entities that are becoming more and Rosai Dorfman disease (RDD) including subsections on recognized as our understanding of the molecular pathogenesis lead pathogenesis, clinical diagnostic criteria and novel insights into to novel diagnostic tests and targeted drug development. A treatment. Details of other histiocytic disorders as well as the symposium held at the American Society of Pediatric Hematology/ standard treatment guidelines have been published elsewhere and Oncology (ASPHO) 2013 Annual Meeting discussed new insights are beyond the scope of this discussion [Haupt et al. (2013). Pediatr into histiocytic disorders. This review highlights the symposium Blood Cancer 60:175–184; Henter et al. (2007). Pediatr Blood presentations, divided into three sections encompassing Langerhans Cancer 2014;61:1329–1335. # 2014 Wiley Periodicals, Inc. cell histiocytosis (LCH), hemophagocytic lymphohistiocytosis (HLH) Key words: hemophagocytic lymphohistiocytosis; Langerhans cell histiocytosis; Rosai Dorfman disease; targeted therapies INTRODUCTION frequency ranging from 38% to 57% [8–12]. A novel somatic mutation in BRAF and germline variants of (T599A) BRAF have Histiocytoses describe a diverse group of proliferative disorders also been described in patients with LCH, though the significance of involving dentritic cells and macrophages. They include a spectrum these observations remains to be defined [10–12]. The frequency of of diseases including a reactive inflammatory accumulation of cells, the somatic BRAF-V600E mutation implies functional significance pathologic immune activation, or neoplastic clonal proliferation. in LCH pathogenesis, but no clinical correlations with BRAF Advanced molecular technologies are resulting in new break- genotype have been established. BRAF is an intermediate kinase in throughs in understanding the pathophysiology of histiocytic the RAS-RAF-MEK-ERK pathway that transduces extracellular disorders that are changing the field. The purpose of this update signals to the nucleus. Phosphorylation of BRAF induces activation report is to aid in understanding the subtle differences in of downstream extracellular signal-regulated kinase (ERK) [8]. The pathogenesis of three most common histiocytic disorders— V600E mutation renders BRAF constitutively active, impacting Langerhans cell histiocytosis (LCH), hemophagocytic lymphohis- several cell functions including cell proliferation and migration. tiocytosis (HLH), and Rosai Dorfman disease (RDD) and how new BRAF activation is insufficient to fully transform cells, as BRAF- insights lead to the hope for novel therapeutics (Table I). V600E has been identified in not only malignancies, including melanoma, papillary thyroid carcinoma, and gliomas, but also in LANGERHANS CELL HISTIOCYTOSIS (LCH) skin nevi and colon polyps [13–15]. Malignant transformation versus immune dysregulation has Pathogenesis been a major focus of LCH research for the past 40 years, with “Langerhans” in LCH refers to Dr. Paul Langerhans (1847– supporting data for both mechanisms. While molecular mecha- 1888) who first described normal epidermal dendritic cells (DCs) nisms are being further explored, many studies have investigated that later were recognized as having some similarity to LCH-lesion inflammation within the LCH lesion. In addition to the pathologic DCs, though he initially thought those cells were neuronal cells due LCs, LCH lesions are characterized by an inflammatory infiltrate to their notable dentritic processes. However, despite epidermal typically including macrophages, eosinophils and lymphocytes DCs having phenotypic features of cutaneous Langerhans cells (LCs), data comparing transcriptomes of purified epidermal LCs to CD207þ cells in LCH lesions found relatively distinct gene 1Children’s Cancer Center, Staten Island University Hospital, Staten expression profiles, with the LCH CD207þ cells having increased Island, New York; 2Center for Infectious Medicine, Karolinska expression of genes associated with immature myeloid precur- Institute, Stockholm, Sweden; 3Department of Pediatrics, Baylor sors [1]. Studies of mouse and human DCs also suggest that College of Medicine, Texas Children’s Cancer Center, Houston, Texas; 4Garron Family Cancer Center, The Hospital for Sick Children, langerin/CD207 expression is not limited to epidermal LCs, but 5 occurs in many lineages at different anatomic sites [2–4]. Ontario, Toronto, Canada; Department of Hematology/Oncology, The Hospital for Sick Children, Ontario, Toronto, Canada Therefore, it is possible that LCH may have an origin distinct † from the epidermal LC. Director, Children’s Cancer Center. The pathogenesis of LCH remains unresolved. Clonality of LCH ‡Assistant Professor. was described many years ago [5,6]. Although a key feature of a #Professor of Pediatrics, Division Head, Director. neoplasm is its clonal derivation from a single cell, clonality does § not necessarily mean malignancy. Willman et al. [7] defined the Associate Professor. clonal cells in LCH as CD1aþ dentritic cells. Advances in DNA ÃCorrespondence to: Sarah R. Vaiselbuh, Department of Pediatrics, sequencing technology enabled sensitive screening of CD1aþ cells Staten Island University Hospital, 256C Mason Ave., Staten Island, NY purified from LCH lesions, and it was discovered that BRAF-V600E 10305. E-mail: [email protected] point mutations were present in the majority of LCH lesions with a Received 3 September 2013; Accepted 10 February 2014 C 2014 Wiley Periodicals, Inc. DOI 10.1002/pbc.25017 Published online 9 March 2014 in Wiley Online Library (wileyonlinelibrary.com). 1330 Vaiselbuh et al. TABLE I. Classification of Three Most Common Histiocytic Disorders Histiocytic disorder Cell type Reported mutations Molecular markers Langerhans cell histiocytosis (LCH) Dentritic cells Yes (50–57%) CD207þþ BRAF-V600E CD1aþþ S100þþ Hemophagocytic lymphohistiocytosis (HLH) Macrophages PRF1 CD163þþþ CD8þ T-lymphocytes UNC13D S100þ/À Natural killer-cells STX11 CD1aÀ STXBP2 Rosai Dorfman disease (RDD) Macrophages No CD14þ, HLA-DRþ CD68þþ, CD163þ S100þ, fascinþ CD1aÀ CD207À with enrichment of regulatory CD4þCD25þT cells [16]. The warrant systemic treatment even as single lesions. Neurodegenera- lesion-LCs express high levels of T-cell stimulatory molecules as tive LCH seems to be a separate entity with a clinical presentation of well as pro-inflammatory cytokines. In addition to the intralesional symptoms of dysarthria, ataxia, and cognitive defects resembling cytokine storm, increased serum levels of pro-inflammatory cyto- multiple sclerosis. kines and chemokines are documented in active LCH [1,16–18]. Pathogenesis that defines disease subclasses of LCH needs further Treatment elucidation. A specific role for lL17A and its receptor in LCH Due to incomplete understanding of the pathogenesis of LCH, pathogenesis has been reported, though IL17A expression by LCH treatment has relied on empiric strategies. Outcomes have improved lesion DCs remains to be validated [19,20]. over the past decades despite few changes in the treatment backbone, possibly due to improved supportive care. In the most Diagnosis recent Histiocyte Society trial, LCH-III, patients with “Low-Risk” LCH had nearly 100% overall survival, while patients with “High- LCH, the most common histiocytic disorder in humans, is Risk” LCH had 84% 5-year overall survival [23]. Other important estimated to occur in approximately five children per million, but factors are the repetition of induction phase of therapy for all may arise de novo in adults [21]. No screening tests are available patients who did not achieve a very good response after the first and the diagnosis is often delayed. While the range of presentations 6 weeks of induction, and an early move to salvage therapy for poor can make LCH a challenging disease to diagnose, tissue biopsy responders who have a very high mortality otherwise. In all patients is diagnostic with pathologic CD207þ and/or CD1aþ DCs in a with LCH, optimizing therapy remains a challenge since background of inflammatory cells. Clinically, symptoms of LCH approximately one-half of all patients with MS-LCH still have depend on the organs involved. Pulmonary LCH might present with refractory/recurrent disease when treated with vinblastine/predni- dyspnea and cough, or chest pain, and shortness of breath in the case sone-based strategies [23,24], in contrast to single system disease, of pneumothorax. Bone lesions may lead to bone pain, abnormal which has a lower reactivation rate. Disease- and treatment-related swelling, or pathological fracture. Skin LCH can occur as a long-term effects are also problematic, and are more common in dermatitis rash with vesicles and bullae (more in infancy). Often patients with disease recurrence. While modifications in dose, there is a past history of unresolved seborrheic eczema and oozing duration and timing of chemotherapy along with improved of the external ear canal. Pituitary involvement with onset of supportive care may continue to achieve incremental improvements diabetes insipidus will cause increased thirst and polyuria. Fatigue, in outcomes for patients with LCH, an optimized therapeutic weight loss and low-grade fevers are signs of the general approach requires understanding of disease pathogenesis. inflammatory
Load more

Recommended publications
  • Masaharu Tanaka, Yoshiya Aze, and Tsuneo Fujita Fukui Institute For
    J Toxicol Pathol 7: 371•`377, 1994 THE RELATIONSHIP BETWEEN INCREASED EMPERIPOLESIS INDEX AND SEVERE HEMATOPOIETIC CELL HYPERPLASIA IN THE BONE MARROW OF LPS-TREATED RATS Masaharu Tanaka, Yoshiya Aze, and Tsuneo Fujita FukuiInstitute for SafetyResearch, ONO Pharmaceutial Co., Ltd. Abstract: To investigate the relationship between the frequency of megakaryocytic emperipolesis and the number of hematopoietic cells, the animals were administered lipopolysaccharide (LPS) intravenously at a daily dose of 0.5mg/kg body weight for up to 7days, and histopathology of bone marrow and hematology of peripheral bloods were examined on Hour 2, 8, and 24 and Day 3, 5, and 7 of LPS treatment. Mature neutrophils appeared to be the most common hematocytes engulfed by megakar yocytes. Engulfed blood cells were observed in the demarcation membrane system of mature megakar yocytes. Cell membranes of both megakaryocytes and entering cells were intact. Although megakar yocytic emperipolesis was also found in control rats, its incidence increased markedly in LPS-treated rats which showed hyperplasia of granulocytes and megakaryocytes in their bone marrows. The index of emperipolesis showed a minimal change from 2.25 to 3.04 during the experimental period in control rats, whereas it rose from Hour 8 (9.78) and peaked on Day 3 (46.04) in LPS-treated rats. Hyperplasia of hematopoietic cells such as megakaryocytes and segmented neutrophils also peaked on Day 3 of LPS treatment. These changes suggest that emperipolesis is a phenomenon closely related to severe hematopoietic hyperplasia in the bone marrow. (J Toxicol Pathol 7: 371•`377, 1994) Key words: Emperipolesis, Lipoplolysaccharide, Megakaryocyte, Neutrophil, Rat normal bone marrows, it showed a marked Introduction increase under several pathological conditions; Emperipolesis was introduced by Humble et idiopathic thrombocytopenic purpura4,17, iron al to describe "inside round about wandering" of deficiency anemia 17, malignant tumors 1.4,10,12-18, lymphocytes within malignant cells in tissue etc.
    [Show full text]
  • Cutaneous Neonatal Langerhans Cell Histiocytosis
    F1000Research 2019, 8:13 Last updated: 18 SEP 2019 SYSTEMATIC REVIEW Cutaneous neonatal Langerhans cell histiocytosis: a systematic review of case reports [version 1; peer review: 1 approved with reservations, 1 not approved] Victoria Venning 1, Evelyn Yhao2,3, Elizabeth Huynh2,3, John W. Frew 2,4 1Prince of Wales Hospital, Randwick, Sydney, NSW, 2033, Australia 2University of New South Wales, Sydney, NSW, 2033, Australia 3Sydney Children's Hospital, Randwick, NSW, 2033, Australia 4Department of Dermatology, Liverpool Hospital, Sydney, Sydney, NSW, 2170, Australia First published: 03 Jan 2019, 8:13 ( Open Peer Review v1 https://doi.org/10.12688/f1000research.17664.1) Latest published: 03 Jan 2019, 8:13 ( https://doi.org/10.12688/f1000research.17664.1) Reviewer Status Abstract Invited Reviewers Background: Cutaneous langerhans cell histiocytosis (LCH) is a rare 1 2 disorder characterized by proliferation of cells with phenotypical characteristics of Langerhans cells. Although some cases spontaneously version 1 resolve, no consistent variables have been identified that predict which published report report cases will manifest with systemic disease later in childhood. 03 Jan 2019 Methods: A systematic review (Pubmed, Embase, Cochrane database and all published abstracts from 1946-2018) was undertaken to collate all reported cases of cutaneous LCH in the international literature. This study 1 Jolie Krooks , Florida Atlantic University, was registered with PROSPERO (CRD42016051952). Descriptive statistics Boca Raton, USA and correlation analyses were undertaken. Bias was analyzed according to Milen Minkov , Teaching Hospital of the GRADE criteria. Medical University of Vienna, Vienna, Austria Results: A total of 83 articles encompassing 128 cases of cutaneous LCH were identified.
    [Show full text]
  • Case Report Congenital Self-Healing Reticulohistiocytosis
    Case Report Congenital Self-Healing Reticulohistiocytosis Presented with Multiple Hypopigmented Flat-Topped Papules: A Case Report and Review of Literatures Rawipan Uaratanawong MD*, Tanawatt Kootiratrakarn MD, PhD*, Poonnawis Sudtikoonaseth MD*, Atjima Issara MD**, Pinnaree Kattipathanapong MD* * Institute of Dermatology, Department of Medical Services Ministry of Public Health, Bangkok, Thailand ** Department of Pediatrics, Saraburi Hospital, Sabaruri, Thailand Congenital self-healing reticulohistiocytosis, also known as Hashimoto-Pritzker disease, is a single system Langerhans cell histiocytosis that typically presents in healthy newborns and spontaneously regresses. In the present report, we described a 2-month-old Thai female newborn with multiple hypopigmented flat-topped papules without any internal organ involvement including normal blood cell count, urinary examination, liver and renal functions, bone scan, chest X-ray, abdominal ultrasound, and bone marrow biopsy. The histopathology revealed typical findings of Langerhans cell histiocytosis, which was confirmed by the immunohistochemical staining CD1a and S100. Our patient’s lesions had spontaneously regressed within a few months, and no new lesion recurred after four months follow-up. Keywords: Congenital self-healing reticulohistiocytosis, Congenital self-healing Langerhans cell histiocytosis, Langerhans cell histiocytosis, Hashimoto-Pritzker disease, Birbeck granules J Med Assoc Thai 2014; 97 (9): 993-7 Full text. e-Journal: http://www.jmatonline.com Langerhans cell histiocytosis (LCH) is a multiple hypopigmented flat-topped papules, which clonal proliferative disease of Langerhans cell is a rare manifestation. involving multiple organs, including skin, which is the second most commonly involved organ by following Case Report the skeletal system(1). LCH has heterogeneous clinical A 2-month-old Thai female infant presented manifestations, ranging from benign single system with multiple hypopigmented flat-topped papules since disease to fatal multisystem disease(1-3).
    [Show full text]
  • Megakaryocyte Emperipolesis Mediates Membrane Transfer from Intracytoplasmic Neutrophils to Platelets
    RESEARCH ARTICLE Megakaryocyte emperipolesis mediates membrane transfer from intracytoplasmic neutrophils to platelets Pierre Cunin1, Rim Bouslama1, Kellie R Machlus2, Marta Martı´nez-Bonet1, Pui Y Lee1,3, Alexandra Wactor1, Nathan Nelson-Maney1, Allyn Morris1, Li Guo4, Andrew Weyrich4, Martha Sola-Visner5, Eric Boilard6, Joseph E Italiano2,7, Peter A Nigrovic1,3* 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States; 2Department of Medicine, Hematology Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, United States; 3Department of Medicine, Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, United States; 4Program in Molecular Medicine and Department of Internal Medicine, University of Utah, Salt Lake City, United States; 5Department of Neonatology, Boston Children’s Hospital, Harvard Medical School, Boston, United States; 6Centre de Recherche en Rhumatologie et Immunologie, Centre de Recherche du Centre Hospitalier Universitaire de Que´bec, Faculte´ de Me´decine de l’Universite´ Laval, Que´bec, Canada; 7Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, United States Abstract Bone marrow megakaryocytes engulf neutrophils in a phenomenon termed emperipolesis. We show here that emperipolesis is a dynamic process mediated actively by both lineages, in part through the b2-integrin/ICAM-1/ezrin pathway. Tethered neutrophils enter in membrane-bound vesicles before penetrating into the megakaryocyte cytoplasm. Intracytoplasmic neutrophils develop membrane contiguity with the demarcation membrane system, thereby *For correspondence: [email protected] transferring membrane to the megakaryocyte and to daughter platelets. This phenomenon occurs in otherwise unmanipulated murine marrow in vivo, resulting in circulating platelets that bear Competing interest: See membrane from non-megakaryocytic hematopoietic donors.
    [Show full text]
  • Congenital Self-Healing Reticulohistiocytosis: an Underreported Entity
    Congenital Self-healing Reticulohistiocytosis: An Underreported Entity Michael Kassardjian, DO; Mayha Patel, DO; Paul Shitabata, MD; David Horowitz, DO PRACTICE POINTS • Langerhans cell histiocytosis (LCH) is believed to occur in 1:200,000 children and tends to be underdiagnosed, as some patients may have no symptoms while others have symptoms that are misdiagnosed as other conditions. • Patients with L CH usually should have long-term follow-up care to detect progression or complications of the disease or treatment. copy not Langerhans cell histiocytosis (LCH), also known angerhans cell histiocytosis (LCH), also as histiocytosis X, is a group of rare disorders known as histiocytosis X, is a general term that characterized by the continuous replication of describes a group of rare disorders characterized L 1 a particular white blood cell called LangerhansDo by the proliferation of Langerhans cells. Central cells. These cells are derived from the bone mar- to immune surveillance and the elimination of for- row and are found in the epidermis, playing a large eign substances from the body, Langerhans cells are role in immune surveillance and the elimination of derived from bone marrow progenitor cells and found foreign substances from the body. Additionally, in the epidermis but are capable of migrating from Langerhans cells are capable of migrating from the the skin to the lymph nodes. In LCH, these cells skin to lymph nodes, and in LCH, these cells begin congregate on bone tissue, particularly in the head to congregate on the bone, particularly in the head and neck region, causing a multitude of problems.2 and neck region, causingCUTIS a multitude of problems.
    [Show full text]
  • Congenital Self-Healing Reticulohistiocytosis in a Newborn
    Rizzoli et al. Italian Journal of Pediatrics (2021) 47:135 https://doi.org/10.1186/s13052-021-01082-9 CASE REPORT Open Access Congenital self-healing reticulohistiocytosis in a newborn: unusual oral and cutaneous manifestations Alessandra Rizzoli1, Simona Giancristoforo2* , Cristina Haass1, Rita De Vito3, Stefania Gaspari4, Eleonora Scapillati1, Andrea Diociaiuti2 and May El Hachem2 Abstract Background: Congenital self-healing reticulohistiocytosis (CSHRH), also called Hashimoto-Pritzker disease, is a rare and benign variant of Langerhans cell histiocytosis, characterized by cutaneous lesions without extracutaneous involvement. Case presentation: We present a case of CSHRH with diffuse skin lesions and erosions in the oral mucosa, present since birth and lasting for 2 months, and we perform a review of the literature on Pubmed in the last 10 years. Conclusions: Our case confirm that lesions on oral mucosa, actually underestimated, may be present in patients with CSHRH. Patients affected by CSHRH require a close follow-up until the first years of life, due to the unpredictable course of Langerhans cell histiocytosis, in order to avoid missing diagnosis of more aggressive types of this disorder. Keywords: Congenital self-healing reticulohistiocytosis, CSHRH, Hashimoto-Pritzker disease, Histiocytosis, Newborn Background We report a case of a newborn with cutaneous and Congenital self-healing reticulohistiocytosis (CSHRH), oral mucosa involvement. In addition, a review of the lit- also known as Hashimoto-Pritzker disease, is a rare be- erature was perfomed on Pubmed using the following nign type of Langerhans cell histiocytosis (LCH) de- mesh terms: “Congenital self-healing reticulohistiocyto- scribed in 1973 [1, 2]. sis”, “congenital self-healing Langerhans cell histiocyto- CSHRH manifests generally at birth or during the neo- sis” and “Hashimoto-Pritzker disease”.
    [Show full text]
  • Long-Lasting Christmas Tree Rash" in an Adolescent: Isotopic Response
    Acta Derm Venereol 2002; 82: 288–291 CLINICAL REPORT Long-lasting ``Christmas Tree Rash’’ in an Adolescent: Isotopic Response of Indeterminate Cell Histiocytosis in Pityriasis Rosea? ANDREAS WOLLENBERG, WALTER H. C. BURGDORF, MARTIN SCHALLER and CHRISTIAN SANDER Department of Dermatology and Allergy, Ludwig-Maximilian-University, Munich, Germany A 13-year-old girl developed a non-pruritic pityriasis rosea, followed by other, smaller red macules on her rosea-like rash, which did not respond to topical cortico- trunk (Fig. 1). After 6 months, all individual lesions steroids or UV therapy but persisted for 2 years. The had persisted, grew slowly in size and became in part lymphohistiocytic in ltrate in the upper dermis showed con uent, but neither itched nor caused any distress. A mononuclear cells immunoreactive with S100, CD68, biopsy showed parakeratosis, extravascular and intraepi- factor XIIIa and CD1a. Electron microscopic evaluation dermal erythrocytes and spongiosis, more suggestive of of these cells demonstrated lamellated dense bodies but pityriasis lichenoides but compatible with pityriasis no Birbeck granules, lipid vacuoles or cholesterol crystals. rosea. Over the following 18 months, the lesions Two diagnoses were made: a primarily clinical diagnosis increased further in number and size. Topical cortico- of generalized eruptive histiocytosis and a more cell- steroids and balneophototherapy were ineVective. biology-based diagnosis of an indeterminate cell histi- At 15 years of age, the patient was admitted to ocytosis. Three years later, the lesions are showing spon- hospital with about 500, round to oval, con uent, taneous resolution, with loss of erythema and attening. in ltrated, reddish-brown macules and plaques ranging Our patient’s indeterminate cells ful l Rowden’s clas- in size from 5 to 30 mm in a Christmas tree pattern on sical de nition (dendritically shaped epidermal non- the trunk, upper arms and legs (Fig.
    [Show full text]
  • REVIEW the Bone Marrow Niche: Habitat to Hematopoietic
    Leukemia (2008) 22, 941–950 & 2008 Nature Publishing Group All rights reserved 0887-6924/08 $30.00 www.nature.com/leu REVIEW The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites Y Shiozawa1, AM Havens2, KJ Pienta3 and RS Taichman1 1Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA; 2Harvard School of Dental Medicine, Boston, MA, USA and 3Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan School of Medicine, Ann Arbor, MI, USA In post-fetal life, hematopoiesis occurs in unique microenvir- In the marrow, bone marrow stromal cells derived from onments or ‘niches’ in the marrow. Niches facilitate the mesenchymal stem cells (MSCs) are believed to provide the maintenance of hematopoietic stem cells (HSCs) as unipotent, while supporting lineage commitment of the expanding blood basis for the physical structures of the niche. As such, bone populations. As the physical locale that regulates HSC function, marrow stromal cells are thought to regulate self-renewal, the niche function is vitally important to the survival of the proliferation and differentiation of the HSCs through production organism. This places considerable selective pressure on of cytokines and intracellular signals that are initiated by cell- HSCs, as only those that are able to engage the niche in the to-cell adhesive interaction.4 Bone marrow stromal cells are appropriate context are likely to be maintained as stem cells. composed of cells of mesenchymal origin known to include Since niches are central regulators of stem cell function, it is 5 not surprising that molecular parasites like neoplasms are osteoblasts, endothelial cells, fibroblasts and adipocytes.
    [Show full text]
  • Unusual Variants of Non-Langerhans Cell Histiocytoses
    REVIEWS Unusual variants of non-Langerhans cell histiocytoses Ruggero Caputo, MD,a Angelo Valerio Marzano, MD,a Emanuela Passoni, MD,a and Emilio Berti, MDb Milan, Italy Histiocytic syndromes represent a large, heterogeneous group of diseases resulting from proliferation of histiocytes. In addition to the classic variants, the subset of non-Langerhans cell histiocytoses comprises rare entities that have more recently been described. These last include both forms that affect only the skin or the skin and mucous membranes, and usually show a benign clinical behavior, and forms involving also internal organs, which may follow an aggressive course. The goal of this review is to outline the clinical, histologic, and ultrastructural features and the course, prognosis, and management of these unusual histiocytic syndromes. ( J Am Acad Dermatol 2007;57:1031-45.) istiocytic syndromes represent a large, puzzling group of diseases resulting from Abbreviations used: proliferation of cells called histiocytes.1 BCH: benign cephalic histiocytosis H ECD: Erdheim-Chester disease The term ‘‘histiocyte’’ includes cells of both the GEH: generalized eruptive histiocytosis monocyte-macrophage series and the Langerhans HPMH: hereditary progressive mucinous cell (LC) series, both antigen-processing and anti- histiocytosis 1 IC: indeterminate cell gen-presenting cells deriving from CD34 progeni- ICH: indeterminate cell histiocytosis tor cells in the bone marrow. JXG: juvenile xanthogranuloma In 1987, the Histiocyte Society proposed a classi- LC: Langerhans cell LCH: Langerhans cell histiocytoses fication of histiocytic syndromes based on 3 classes: MR: multicentric reticulohistiocytosis (1) class I, corresponding to LC histiocytoses (LCH); PNH: progressive nodular histiocytosis (2) class II, encompassing the histiocytoses of mon- PX: papular xanthoma onuclear phagocytes other than LC (non-LCH); and SBH: sea-blue histiocyte 2 SBHS: sea-blue histiocytic syndrome (3) class III, comprising the malignant histiocytoses.
    [Show full text]
  • Emperipolesis in a Juvenile Xanthogranuloma: Sentinel Case Report and Review of the Literature
    Case Report Annals of Clinical Case Reports Published: 26 Nov, 2018 Emperipolesis in a Juvenile Xanthogranuloma: Sentinel Case Report and Review of the Literature Kurt J Knowles1*, Shoujun Chen1, Kathryn Rhymes2, Kevin Boykin2 and Ailing Li1 1Department of Pathology and Translational Pathobiology, LSU Health Science Center Shreveport, USA 2Department of Pediatric Surgery, LSU Health Science Center enter Shreveport, USA Abstract This is the first reported case of a giant juvenile xanthogranuloma with multiple unusual features. The patient is an infant who presented with a rapidly growing 4.0 cm soft tissue mass on the back with necrosis and ulceration. MRI demonstrated the characteristic signaling of sebaceous cyst. Histology revealed a large and well-circumscribed dermal lesion that is composed predominately of histiocytes, lymphocytes, eosinophils, multinucleated giant cells, Touton giant cells and the extremely unique feature consisting of an extraordinarily high degree of emperipolesis. The diagnosis of juvenile xanthogranuloma is confirmed by positive immunostaining for CD68 and CD163, and negative immunostaining for CD1a, CD117 and S100 ruled out a Langerhans cell lesion. The final diagnosis is giant juvenile xanthogranuloma with emperipolesis simulating Rosai-Dorfman Disease, a lesion that has never been reported, and may represent a mixture of a dendritic cell related tumor and a macrophage related tumor according to the 1997 WHO classification of histiocytic lesions. Keywords: Xanthogranuloma; Juvenile; Emperipolesis; Non-Langerhans cell histiocytosis Introduction Juvenile Xanthogranuloma (JXG) is a non-Langerhans histiocytic proliferative disorder most common in infancy or childhood although cases in adult and elderly patients have been reported OPEN ACCESS [1,2]. JXG presents with one or more cutaneous or subcutaneous nodules often occurring in head *Correspondence: and neck but also on trunk and extremities.
    [Show full text]
  • A Case of Generalized Eruptive Histiocytosis
    Acta Derm Venereol 2007; 87: 533–536 CLINICAL REPORT A Case of Generalized Eruptive Histiocytosis Beatriz FERNÁNDEZ-JORGE1, Jaime GODAY-BUJÁN1, Jesús DEL POZO LOSADA1, Roberto ÁlvaREZ-RODRÍGUEZ2 and Eduardo FONSECA Departments of 1Dermatology and 2Pathology, Hospital Juan Canalejo, A Coruña, Spain Histiocytoses are a heterogeneous group of diseases, proliferation of benign histiocytes without deposition of characterized by the accumulation of reactive or neo­ lipids, iron or mucine. Electron microscopy reveals that plastic histiocytes in various tissues. Generalized erup­ these cells may possess various markers, such as comma- tive histiocytosis belongs to cutaneous non­Langerhans’ shaped bodies, dense bodies and regularly laminated cell histiocytoses and is a rare, generalized, self­healing bodies, but no Birbeck granules. Herein we report a case disorder that usually follows a benign clinical course. of GEH in a 41-year-old woman with peculiar clinical Herein, we report a case of generalized eruptive histio­ and immunohistochemical features. cytosis in a 41­year­old woman with peculiar clinical and histological features. Clinically, the papules showed a marked distribution into the seborrhoeic areas of the Case REPORT trunk, with a great tendency to coalesce. Furthermore, A 41-year-old woman presented with a 3-month history immunohistochemical labelling demonstrated that the of progressive appearance of brown to reddish and histiocytes were positive for CD68, but negative for slightly elevated macules and papules, symmetrically CD34, S100, CD1a and XIIIa factor. This is the second distributed on the seborrhoeic areas of the trunk and report of generalized eruptive histiocytosis with a nega­ extensor surface of both upper arms (Figs 1 and 2).
    [Show full text]
  • Langerhans Cell Histiocytosis Nanette Grana, MD
    LCH is a rare and often underdiagnosed histiocytic disorder with an unknown etiology. White Butterfly. Photograph courtesy of Sherri Damlo. www.damloedits.com. Langerhans Cell Histiocytosis Nanette Grana, MD Background: Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder of unknown etiopathogenesis. Its clinical presentation is variable and ranges from isolated skin or bone disease to a life-threatening multisystem condition. LCH can occur at any age but is more frequent in the pediatric population. A neoplastic origin of this disease has been suggested due to the discovery of the mutually exclusive activating somatic BRAF V600E and MAP2K1 gene mutations that occur in about 75% of patients. Methods: A survey of recent literature focused on the diagnosis, management, and prognosis of Langerhans cell histiocytosis. Data were collected, analyzed, and discussed with an emphasis on contemporary clinical practice. Results: LCH is common in the pediatric population; compared with adults, children usually have a more aggressive clinical course that requires systemic chemotherapy. Patients with low-risk LCH have an excellent prognosis and a long-term survival rate that may be as high as 99%; by contrast, patients with high-risk LCH have a survival rate close to 80%. Typically, adult patients present with limited skin or bone involvement that can be treated with surgical resection or focal radiation therapy, resulting in an overall survival rate of 100%. Smoking cessation can result in the improvement of respiratory symptoms and the spontaneous resolution of pulmonary LCH. Targeted therapy with BRAF inhibitors has been used in select patients with LCH, and the results have been encouraging.
    [Show full text]